John D Powderly

John D Powderly

UNVERIFIED PROFILE

Are you John D Powderly?   Register this Author

Register author
John D Powderly

John D Powderly

Publications by authors named "John D Powderly"

Are you John D Powderly?   Register this Author

15Publications

4131Reads

6Profile Views

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Differential drug responses of circulating tumor cells within patient blood.

Cancer Lett 2014 Sep 21;352(1):28-35. Epub 2013 Aug 21.

Department of Biomedical Engineering, Cornell University, Ithaca, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.08.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997656PMC
September 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

Rapid isolation of viable circulating tumor cells from patient blood samples.

J Vis Exp 2012 Jun 15(64):e4248. Epub 2012 Jun 15.

Department of Biomedical Engineering, Cornell University, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/4248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471307PMC
June 2012

Microtube device for selectin-mediated capture of viable circulating tumor cells from blood.

Clin Chem 2012 May 16;58(5):846-53. Epub 2012 Feb 16.

Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2011.176669DOI Listing
May 2012

Host absence of CCR5 potentiates dendritic cell vaccination.

J Immunol 2003 Apr;170(8):4201-8

Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.170.8.4201DOI Listing
April 2003